NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee D meeting minutes

**Minutes:** Confirmed

**Date:** Thursday 9 May 2024

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Megan John (Chair) Present for all items
2. Dr Raju Reddy (Vice-chair) Present for all items
3. Martin Bradley Present for all items
4. Dr Matthew Bradley Items 5.1 to 5.2.2
5. Paul Caulfield Items 1.1 to 5.2.1
6. Professor Sofia Dias Present for all items
7. Andrew Fox Present for all items
8. Dr David Foreman Items 1.1 to 4.2.2
9. Dr Robert Hodgson Present for all items
10. Dr Bernard Khoo Present for all items
11. Dr Ivan Koychev Items 1.1 to 4.1.3,

Items 5.1 to 5.2.1

1. Dr Guy Makin Present for all items
2. Dr Philip Mallender Present for all items
3. Professor David Meads Present for all items
4. Giles Monnickendam Items 1.1 to 4.2.2
5. Dr Nathan Moore Items 1.1 to 5.2.1
6. Dr Paula Parvulescu Items 1.1 to 5.2.1
7. Carole Pitkeathley Present for all items
8. Dr Ben Searle Present for all items
9. Sophia Steer Items 1.1 to 5.2.1
10. Will Sullivan Present for all items
11. Dr Zenas Yiu Present for all items

NICE staff (key players) present

Ross Dent, Associate Director Items 1.1 to 4.2.2

Louise Jafferally, Project Manager Items 1.1 to 4.2.2

Lizzie Walker, Heath Technology Assessment Adviser Items 1.1 to 4.2.2

Owen Swales, Heath Technology Assessment Analyst Items 1.1 to 4.2.2

Jasdeep Hayre, Associate Director Items 5.1 to 5.2.2

Kate Moore, Project Manager Items 5.1 to 5.2.2

Alan Moore, Heath Technology Assessment Adviser Items 5.1 to 5.2.2

Ross Wilkinson, Heath Technology Assessment Analyst Items 5.1 to 5.2.2

External assessment group representatives present

Marie Westwood, Kleijnen Systematic Reviews Items 1.1 to 4.1.3

Sabine Grimm, Kleijnen Systematic Reviews Items 1.1 to 4.1.3

Dr Jo Picot, Southampton Health Technology Assessments Centre,

Items 5.1 to 5.1.3

Dr Keith Cooper, Southampton Health Technology Assessments Centre,

Items 5.1 to 5.1.3

Clinical, Patient & NHS England experts present

Professor Elizabeth Coulthard, Professor of Cognitive Neurology, clinical expert, nominated by Alzheimer’s Research UK Items 1.1 to 4.1.3

Dr Richard Perry, Consultant Neurologist and Honorary Senior Lecturer, clinical expert, nominated by Eisai Items 1.1 to 4.1.3

David Thomas, Head of Policy, Access & Innovation, Alzheimer’s Research UK, patient expert, nominated by Alzheimer’s Research UK Items 1.1 to 4.1.3

Larry Woelk, Patient expert, nominated by Alzheimer’s Research UK

Items 1.1 to 4.1.3

Rita Woelk, Partner of patient expert Larry Woelk Items 1.1 to 4.1.3

Ann Jarvis, Commissioning expert, nominated by NHS England

Items 1.1 to 4.1.3

Ewan Maule, Commissioning expert, nominated by NHS North East and North Cumbria ICB Items 1.1 to 4.1.3

Dr Sanjeev Patel, IMF Lead, NHS England Items 1.1 to 5.2.1

Frances Copeland, Patient expert, nominated by Muscular Dystrophy UK

Items 5.1 to 5.1.3

Charlotte Campbell, Research & Partnerships Officer at Myaware, patient expert, nominated by Myaware Items 5.1 to 5.1.3

Dr Channa Hewamadduma, Consultant Neuromuscular Neurologist and Honorary Senior Lecturer, clinical expert, nominated by Argenx Items 5.1 to 5.1.3

Dr Fiona Norwood, Consultant Neurologist – clinical expert, nominated by Myaware

Items 5.1 to 5.1.3

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The Chair, Dr Megan John, welcomed members of the committee and other attendees present to the meeting.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Thursday 4 April 2024.

### Appraisal of lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease [ID4043]

* 1. Part 1 – Open session
     1. The Chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Eisai.
     2. The Chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11220).
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Carole Pitkeathley, Andrew Fox, and Professor David Meads.
  2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11220>

### Appraisal of efgartigimod for treating generalised myasthenia gravis [ID4003]

* 1. Part 1 – Open session
     1. The Chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Argenx.
     2. The Chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10986).
     3. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by the Chair.
  2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives, and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10986>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee D will be held on Thursday 6 June 2024 and will start promptly at 09:00am.